This Article Abstract Full Text (PDF) All Versions of this Article: 110/3/247    most recent 01.CIR.0000135472.28234.CCv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nerheim, P. Articles by Olshansky, B. Search for Related Content PubMed PubMed Citation Articles by Nerheim, P. Articles by Olshansky, B. Related Collections Cardio-renal physiology/pathophysiology Structure Contractile function Other heart failure Cardiovascular Pharmacology Secondary prevention Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2004;110:247-252.)
© 2004 American Heart Association, Inc.

Original Articles

Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia

Pamela Nerheim, MD; Sally Birger-Botkin, RN; Lubna Piracha, DO; Brian Olshansky, MD

From the University of Iowa Hospitals, Iowa City, and Loyola University Medical Center, Maywood, Ill.

Correspondence to Brian Olshansky, MD, Director, Cardiac Electrophysiology, University of Iowa Hospital, 200 Hawkins Dr, Iowa City, IA 52242–1081. E-mail brian-olshansky{at}uiowa.edu

Received May 13, 2003; de novo received February 8, 2004; revision received March 23, 2004; accepted March 29, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Background— Tachycardia-induced cardiomyopathy is a reversible cause of heart failure. We hypothesized that although left ventricular ejection fraction measurements normalize after heart rate or rhythm control in patients with tachycardia-induced cardiomyopathy, recurrent tachycardia may have abrupt and deleterious consequences.

Methods and Results— Patients with tachycardia-induced cardiomyopathy that developed over years were evaluated and treated. Tachycardia episodes and outcomes were assessed. Twenty-four patients were identified. All had NYHA functional class III heart failure or greater on presentation. One third were heart transplant candidates. There were 17 men and 7 women with a mean age of 46±16 years and mean left ventricular ejection fraction of 0.26±0.09 at the index visit. The cause was atrial fibrillation (n=13), atrial flutter (n=4), atrial tachycardia (n=3), idiopathic ventricular tachycardia (n=1), permanent junctional reciprocating tachycardia (n=2), and bigeminal ventricular premature contractions (n=1). Within 6 months of rate control or correction of the rhythm, left ventricular ejection fraction improved or normalized and symptoms abated in all. Five patients had tachycardia recur. In these patients, left ventricular ejection fraction dropped precipitously and heart failure ensued within 6 months, even though the initial impairment took years. Rate control eliminated heart failure and improved or normalized ejection fraction in 6 months. Three of 24 patients died suddenly and unexpectedly.

Conclusions— Tachycardia-induced cardiomyopathy develops slowly and appears reversible by left ventricular ejection fraction improvement, but recurrent tachycardia causes rapid decline in left ventricular function and development of heart failure. Sudden death is possible.

Key Words: arrhythmia • death, sudden • heart failure • heart rate • tachycardia

	Introduction

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Tachycardia-induced cardiomyopathy (TIC), a cause of heart failure and impaired left ventricular function, is considered reversible. Left ventricular systolic function, measured by left ventricular ejection fraction (LVEF), improves or normalizes and symptoms resolve if tachycardia is controlled with medication^1,2 or ablation.^3–11 TIC has been described in patients of all ages, in heart transplant patients,¹² and even in utero.¹³ Rhythms causing TIC include atrial fibrillation,^14–16 atrial flutter,¹⁷ supraventricular tachycardia,^{3,4,8,10,12,18} ventricular tachycardia,^5–7,19,20 fascicular tachycardia,² ventricular ectopy,²¹ and even persistent rapid DDD pacing.²² Recurrent tachycardia after apparent resolution of TIC has been described, but the consequences have not been quantified completely.¹⁵

This report addresses the issue of recurrent tachycardia in patients with prior, apparently resolved, TIC. We hypothesized that although LVEF measurements may improve or normalize after rate or rhythm control in patients with TIC, recurrent tachycardia is associated with rapid development of symptomatic heart failure and a precipitous decline in left ventricular systolic function.

	Methods

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Study Patients
Patients with heart failure and tachycardia referred to the electrophysiology service were screened. For the patient to be included, no condition other than tachycardia-explained cardiomyopathy and significant improvement in LVEF and symptoms after heart rhythm or rate control was required.

Twenty-four patients (17 men, 7 women) qualified over a 12-year period. The investigators followed up all patients. Their mean age was 46±16 years (range, 22 to 78 years) and mean LVEF was 0.26±0.09 (range, 0.10 to 0.40) at the index visit. LVEF was measured subsequently as indicated. LVEF was evaluated by echocardiography (n=44), radionuclide angiography (n=19), and/or ventriculography during cardiac catheterization (n=3).

Data Collection
The following information was confirmed by chart review after approval from our Institutional Review Board: (1) treatment for TIC, (2) evaluation of symptoms at all follow-up visits, (3) duration of tachycardia before the index assessment for heart failure, (4) time to improvement of LVEF and symptoms, (5) onset of symptoms and impaired LVEF in patients with recurrent tachycardia, and (6) long-term outcome.

Statistical Analysis
A Wilcoxon signed-ranks test was used to compare the LVEF obtained at the index visit for initial heart failure symptoms with the LVEF after rate or rhythm correction. Similarly, this test was used to compare the time to symptom onset for the initial episode of tachycardia to the time of symptom onset for the first recurrent episode (for those with recurrence). The Mann-Whitney test was used for between-group comparisons. Exact-distribution tests were used because of sample size.

	Results

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Initial Presentation
Twenty-four patients had NYHA functional class III or IV heart failure, and 8 were considered heart transplantation candidates when TIC was first suspected (the "index visit" under our care). Despite medical therapy, all patients continued to have heart failure symptoms until tachycardia resolved. Arrhythmia persisted for a median of 4.2 years and a mean of 8.0±9.1 years (range, 1 to 30 years) before heart failure symptoms and impaired LVEF were noted.

Causes and Treatment of TIC
The arrhythmic cause for TIC was atrial fibrillation (n=13), atrial flutter (n=4), atrial tachycardia (n=3), permanent junctional reciprocating tachycardia (n=2), idiopathic ventricular tachycardia (n=1), and bigeminal premature ventricular contractions (n=1) (Table 1). Therapies to control tachycardia included radiofrequency ablation in all patients with atrial flutter, atrial tachycardia, and permanent junctional reciprocating tachycardia and in the patient with bigeminal premature ventricular contractions. Two patients with atrial fibrillation had AV junctional ablation, and 12 required medications. Patients with atrial fibrillation received digoxin, amiodarone, ß-blockers, and/or calcium-channel blockers. One patient with atrial fibrillation had supraventricular tachycardia and underwent an unsuccessful right-sided pathway ablation attempt. Another with atrial fibrillation ultimately developed atrial flutter and underwent an atrial flutter ablation procedure.

View this table: [in this window] [in a new window]   TABLE 1. Clinical Characteristics

One patient with an atypical form of idiopathic right ventricular tachycardia had several failed ablation attempts. She was lost to follow-up and took no medication for 8 years. Heart failure ensued, and her LVEF plummeted to 0.15. Suppression of nearly incessant ventricular tachycardia with amiodarone normalized the LVEF and eliminated symptoms.

Ultimately, slowing of the ventricular rate occurred in all patients with treatment. With resolution of tachycardia or with rate control, all patients became asymptomatic, and all LVEFs approached normal.

The mean LVEF before treatment was 0.26±0.09 (range, 0.10 to 0.40). After treatment and with clinical improvement, the mean LVEF was 0.51±0.05 (range, 0.45 to 0.65) (Wilcoxon signed-ranks S=150; n=24; P<0.0001). Of the 24 patients, 20 had evaluation of LVEF within 2 years of treatment. The mean time to improvement of the LVEF was 5.8±4.8 months. The time course for symptom resolution mirrored the improvement in LVEF. Echocardiographic dimensions before and after therapy are shown in Table 2.

View this table: [in this window] [in a new window]   TABLE 2. Echocardiographic Dimensions

Recurrent Tachycardia
Rapid Decline in LVEF and Reemergence of Heart Failure
Five of 24 patients had tachycardia recur. In all patients, it was atrial fibrillation (1 also had atrial flutter). Three of these 5 patients had >1 recurrence. LVEF declined and heart failure symptoms developed within 6 months of identification of recurrent tachycardia. This was much faster than the initial decline for each patient: 96±109 months (range, 12 to 360 months) versus 7.2±6.4 months (Wilcoxon signed-ranks test, 2-tailed exact P=0.0625).

Example
A 33-year-old woman developed TIC as a result of >8 years of uncontrolled atrial fibrillation. Symptoms resolved and LVEF normalized with treatment. Atrial fibrillation recurred 2 years later, and LVEF dropped precipitously with heart failure symptoms within 6 months. Rate control eliminated symptoms and normalized LVEF within 1 to 3 months. Several months later, after neglecting to take her medication, heart failure symptoms recurred, and LVEF dropped. Symptoms disappeared and LVEF normalized after amiodarone (Figure 1).

View larger version (17K): [in this window] [in a new window]   Figure 1. Changes in LVEF in 33-year-old woman with recurrent atrial fibrillation. Cardioverted with Ibutilide, she had recurrence 2 years later (t=24 months). Rate control with metoprolol was unsuccessful. Rhythm control was achieved 4 months later (t=27 months) with amiodarone. At 33 months, her LVEF normalized. At t=43, she stopped amiodarone, and heart failure symptoms developed. Three months later (t=46), her LVEF was 0.25. Amiodarone was restarted. Symptoms disappeared 1 month later, and LVEF normalized.

Sudden Death
An unexpected but important finding was that 3 patients died suddenly. The patients (42, 36, and 44 years of age) had atrial fibrillation that caused cardiomyopathy (Table 3). None had new symptoms, and all had NYHA functional class I heart failure immediately before sudden, unexpected death, according to witnesses. For patients who died, the last measured LVEF approximated 0.50. No patient had evidence of or symptoms related to loss of rate control at the last evaluation.

View this table: [in this window] [in a new window]   TABLE 3. Characteristics of Patients With Sudden Death

Cases of Sudden Cardiac Death
Patient 1
A 41-year-old man with untreated atrial fibrillation since he was 15 years of age had persistent tachycardia, developed class III heart failure and syncope, and had an LVEF of 0.10. Amiodarone administration did not maintain sinus rhythm but did slow the ventricular response. Four months later, his LVEF improved to 0.55, and he was asymptomatic. Five months later, amiodarone was stopped, and a ß-blocker was started. He died suddenly and unexpectedly 4 months later.

Patient 2
A 26-year-old man had longstanding (>10 years) uncontrolled atrial fibrillation with a heart rate of >195 bpm with minimal exertion, class III heart failure, and impaired LVEF. Over a 10-year follow-up, he was treated with amiodarone and multiple cardioversions. LVEF improved markedly (and symptoms disappeared) within a month after each cardioversion but dropped precipitously (associated with heart failure) within 4 to 8 weeks after recurrence of rapid rates. Ultimately, he underwent AV junctional ablation and pacemaker implantation. Symptoms resolved, and LVEF was normal for several years. While gardening, he was noted to slump over and die suddenly.

Patient 3
A 44-year-old man had atrial fibrillation for 18 months and noted heart failure symptoms 1 week before his index visit. His LVEF was 0.10, and symptoms did not improve with standard heart failure therapy. Cardioversion 1 month later improved his LVEF to 0.48, and the symptoms resolved. Although atrial fibrillation recurred 6 months later, the rate was controlled. Without symptoms, he died suddenly at home.

The 3 patients who died suddenly had an index LVEF that was significantly less than that of the entire group (Mann-Whitney test, exact P<0.034; see Figure 2).

View larger version (10K): [in this window] [in a new window]   Figure 2. LVEF of those who died vs that of other patients. Index LVEF of those who died was less than that for the others (Mann-Whitney test, exact P<0.034). Solid dots represent index LVEF for those who died.

	Discussion

Top Abstract Introduction Methods Results Discussion Conclusions References

 
TIC is considered a reversible condition on the basis of resolution of symptoms and normalization of the LVEF after the rhythm is corrected or the rate is controlled.^8,15 The heart dilates, LVEF decreases, but hypertrophy does not occur. The time course to recovery has been evaluated. In 8 patients with atrial fibrillation for 10±9 months,²³ LVEF normalized in 1 month.

Similar to previous reports,^{2,5–8,10,14–16,22} our data show recovery in the LVEF and resolution of symptoms after treatment. Our report is the first to show that despite apparent resolution of the problem, tachycardia recurrence causes a precipitous decline in LVEF with concomitant symptoms and that there is an association with sudden cardiac death. Our study is the first to quantify the time course of symptom development and the rapidity of impairment of the LVEF with tachycardia recurrence. Other than our report, we know of only 1 other report of 3 patients who had apparent reversible and recurrent tachycardia.¹⁵

A precipitous drop in the LVEF with tachycardia recurrence suggests persistent ultrastructural changes making the left ventricle susceptible to repeated stress. A permanent change, not measurable by the LVEF or by symptoms, may occur in the left ventricle.

Other data support this finding. Biopsies of 2 young patients with TIC showed mild hypertrophy and focal interstitial fibrosis in 1 patient and mild to moderate cellular hypertrophy with focal degenerative changes and mild to moderate interstitial edema in the other.¹ Persistent ultrastructural changes in animal models suggest other possibilities.

Animal Models
Rapid pacing can initiate cardiomyopathy in animals.^24–28 Eble and Spinale,²⁹ studying the contractile and cytoskeletal structure in pigs with pacing-induced cardiomyopathy, showed ventricular dilatation without hypertrophy similar to that seen in humans. In a canine model, Kajstura et al³⁰ found no change in heart weights but observed myocyte replacement with fibrosis. Left ventricular torsional abnormalities²⁷ and mitral regurgitation³¹ occur in sheep. Independent of LVEF measurements, myocyte elongation and misalignment and disruption of basement membrane/sarcolemmal interfaces³² with developing sarcolemmal festoons³³ and changes in myocyte attachment to laminin, fibronectin, and the extracellular collagen matrix^32,33 may be seen.

Cytoskeletal changes include increased ß-actin, -actin, and -tubulin³⁴; alteration in matrix metalloproteinases (gelatinase, collagenase, and stromolysin)^35,36; and depletion of high energy stores. Atrial natriuretic peptide levels, renin-angiotensin, and endothelin activity change.³⁷

Downregulation of calcium cycling with lower activity of sarcoplasmic reticulum calcium transport based on ryanodine receptor responsiveness³⁸ and accumulation³⁹ occurs. Myofibrillar calcium ATPase activity, sodium-potassium ATPase activity,⁴⁰ and cardiac glycoside binding activity⁴¹ are reduced. As part of the remodeling process, epinephrine and norepinephrine levels increase, probably coupled to decreased sympathetic responsiveness and ß₁ receptor density.

ß-Adrenergic blockers enhance reverse remodeling after myocardial infarction.⁴² Data such as these, while compelling, may not apply to TIC because mechanisms for these conditions differ. The LVEF may be a poor surrogate of remodeling; its normalization may not indicate correction of TIC.⁴³

In paced animal models of TIC, when pacing is stopped, LVEF normalizes, but hypertrophy develops and diastolic dysfunction persists.^43,44 Because myocardial compliance is reduced and ventricular filling is impeded, high heart rates with recurrent tachycardia may result in shortened filling times and rapidly progressive heart failure.

Any or all of these abnormalities could influence the rate at which LVEF falls with recurrent tachycardia. It is not clear which alteration is the chicken and which is the egg.⁴⁵

Sudden Death: A New Finding
Our report is the first to document risk of sudden death in this population even with apparent rate control. Afonso and Franca⁴⁶ reported sudden death in a young man with heart failure and supraventricular tachycardia in whom rate control was not achieved. An echocardiogram showed dilated cardiomyopathy. An endomyocardial biopsy showed mild interstitial infiltration.

In a dog model, Pak et al⁴⁷ sought to determine whether tachycardia-induced heart failure was an effective model for sudden cardiac death. Six of 25 animals (24%) died suddenly. In 1 dog, a monitor documented polymorphic ventricular tachycardia as the cause of death. Holter recordings revealed increasing ventricular tachycardia episodes as heart failure progressed. The corrected QT interval prolonged significantly (311±25 to 338±25 ms; P<0.05), and the monophasic action potential duration (at 90% repolarization) increased from 181±19 to 209±28 ms. Dispersion in monophasic action potential duration rose 40%. Increased cesium chloride sensitivity in myocytes isolated from these failing hearts suggested impaired potassium channel functioning perhaps a precursor to QT prolongation and malignant arrhythmias.

Study Limitations
This study is retrospective, and there was no consistent protocol to measure LVEF. An accurate initial duration of tachycardia and its recurrence were difficult to pinpoint.

	Conclusions

Top Abstract Introduction Methods Results Discussion Conclusions References

 
TIC initially may take years to develop and may appear to resolve with treatment. Those patients who later develop recurrent tachycardia can have rapid recrudescence of symptoms and a precipitous decline in LVEF. Patients with TIC may have a long-term risk for sudden death. These results suggest that despite improvement with treatment, a surreptitious cardiomyopathy caused by unknown ultrastructural changes may persist. Scrupulous, rapid, and aggressive rate control may prevent serious adverse consequences.

	References

Top Abstract Introduction Methods Results Discussion Conclusions References

 

1. McLaran CJ, Gersh BJ, Sugrue DD, et al. Tachycardia induced myocardial dysfunction. A reversible phenomenon? Br Heart J. 1985; 53: 323–327.[Abstract/Free Full Text]
   
2. Anselme F, Boyle N, Josephson M. Incessant fascicular tachycardia: a cause of arrhythmia induced cardiomyopathy. Pacing Clin Electrophysiol. 1998; 21: 760–763.[CrossRef][Medline] [Order article via Infotrieve]
   
3. Chiladakis JA, Vassilikos VP, Maounis TN, et al. Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol. 1997; 20: 953–959.[CrossRef][Medline] [Order article via Infotrieve]
   
4. Cruz FE, Cheriex EC, Smeets JL, et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol. 1990; 16: 739–744.[Abstract]
   
5. Singh B, Kaul U, Talwar KK, et al. Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol. 1996; 19: 1391–1392.[CrossRef][Medline] [Order article via Infotrieve]
   
6. Jaggarao NS, Nanda AS, Daubert JP. Ventricular tachycardia induced cardiomyopathy: improvement with radiofrequency ablation. Pacing Clin Electrophysiol. 1996; 19: 505–508.[CrossRef][Medline] [Order article via Infotrieve]
   
7. Grimm W, Menz V, Hoffmann J, et al. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol. 2001; 24: 166–171.[CrossRef][Medline] [Order article via Infotrieve]
   
8. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986; 57: 563–570.[CrossRef][Medline] [Order article via Infotrieve]
   
9. Rosenqvist M, Lee MA, Moulinier L, et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol. 1990; 16: 1467–1474.[Abstract]
   
10. Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia: a curable cause of congestive cardiomyopathy. JAMA. 1985; 253: 391–392.[Abstract]
    
11. Wu EB, Chia HM, Gill JS. Reversible cardiomyopathy after radiofrequency ablation of lateral free-wall pathway-mediated incessant supraventricular tachycardia. Pacing Clin Electrophysiol. 2000; 23: 1308–1310.[CrossRef][Medline] [Order article via Infotrieve]
    
12. Ott P, Kelly PA, Mann DE, et al. Tachycardia-induced cardiomyopathy in a cardiac transplant recipient: treatment with radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 1995; 6: 391–395.[Medline] [Order article via Infotrieve]
    
13. Harrigan JT, Kangos JJ, Sikka A, et al. Successful treatment of fetal congestive heart failure secondary to tachycardia. N Engl J Med. 1981; 304: 1527–1529.[Medline] [Order article via Infotrieve]
    
14. Manolis AG, Katsivas AG, Lazaris EE, et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Int Cardiac Electrophysiol. 1998; 2: 71–76.
    
15. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992; 69: 1570–1573.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Raymond RJ, Lee AJ, Messineo FC, et al. Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J. 1998; 136: 435–442.[CrossRef][Medline] [Order article via Infotrieve]
    
17. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol. 1998; 32: 205–210.[Abstract/Free Full Text]
    
18. Simmers T, Sreeram N, Wittkampf F. Catheter ablation of sinoatrial re-entry tachycardia in a 2 month old infant. Heart. 2003; 89: e1.[Abstract/Free Full Text]
    
19. Rakovec P, Lajovic J, Dolenc M. Reversible congestive cardiomyopathy due to chronic ventricular tachycardia. Pacing Clin Electrophysiol. 1989; 12: 542–545.[CrossRef][Medline] [Order article via Infotrieve]
    
20. Noe P, Van Driel V, Wittkampf F, et al. Rapid recovery of cardiac function after catheter ablation of persistent junctional reciprocating tachycardia in children. Pacing Clin Electrophysiol. 2002; 25: 191–194.[CrossRef][Medline] [Order article via Infotrieve]
    
21. Chugh SS, Shen WK, Luria DM, et al. First evidence of premature ventricular complex-induced cardiomyopathy: a potentially reversible cause of heart failure. J Cardiovasc Electrophysiol. 2000; 11: 328–329.[Medline] [Order article via Infotrieve]
    
22. Soejima K, Delacretaz E, Stevenson WG, et al. DDD-pacing-induced cardiomyopathy following AV node ablation for persistent atrial tachycardia. J Int Cardiac Electrophysiol. 1999; 3: 321–323.[CrossRef]
    
23. Van Gelder IC, Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 1993; 72: 560–566.[CrossRef][Medline] [Order article via Infotrieve]
    
24. Spinale FG, Zellner JL, Tomita M, et al. Tachycardia-induced cardiomyopathy: effects on blood flow and capillary structure. Am J Physiol. 1991; 261: H140–H148.[Medline] [Order article via Infotrieve]
    
25. Spinale FG, Hendrick DA, Crawford FA, et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol. 1990; 259: H218–H229.[Medline] [Order article via Infotrieve]
    
26. Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol. 1995; 268: H836–H847.[Medline] [Order article via Infotrieve]
    
27. Tibayan FA, Lai DT, Timek TA, et al. Alterations in left ventricular torsion in tachycardia-induced dilated cardiomyopathy. J Thorac Cardiovasc Surg. 2002; 124: 43–49.[Abstract/Free Full Text]
    
28. Byrne MJ, Raman JS, Alferness CA, et al. An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. J Cardiac Failure. 2002; 8: 108–115.[CrossRef][Medline] [Order article via Infotrieve]
    
29. Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol. 1995; 268: H2426–H2439.[Medline] [Order article via Infotrieve]
    
30. Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation. 1995; 92: 2306–2317.[Abstract/Free Full Text]
    
31. Timek TA, Dagum P, Lai DT, et al. Pathogenesis of mitral regurgitation in tachycardia-induced cardiomyopathy. Circulation. 2001; 104 (suppl I): I-47–I-53.[Medline] [Order article via Infotrieve]
    
32. Spinale FG, Zellner JL, Johnson WS, et al. Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol. 1996; 28: 1591–1608.[CrossRef][Medline] [Order article via Infotrieve]
    
33. Zellner JL, Spinale FG, Eble DM, et al. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res. 1991; 69: 590–600.[Abstract/Free Full Text]
    
34. Takahashi M, Tsutsui H, Kinugawa S, et al. Role of microtubules in the contractile dysfunction of myocytes from tachycardia-induced dilated cardiomyopathy. J Mol Cell Cardiol. 1998; 30: 1047–1057.[CrossRef][Medline] [Order article via Infotrieve]
    
35. Coker ML, Thomas CV, Clair MJ, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 1998; 274: H1516–H1523.[Medline] [Order article via Infotrieve]
    
36. King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003; 92: 177–185.[Abstract/Free Full Text]
    
37. Burchell SA, Spinale FG, Crawford FA, et al. Effects of chronic tachycardia-induced cardiomyopathy on the beta-adrenergic receptor system. J Thorac Cardiovasc Surg. 1992; 104: 1006–1012.[Abstract]
    
38. Yamamoto T, Yano M, Kohno M, et al. Abnormal Ca²⁺ release from cardiac sarcoplasmic reticulum in tachycardia-induced heart failure. Cardiovasc Res. 1999; 44: 146–155.[Abstract/Free Full Text]
    
39. Ravens U, Davia K, Davies CH, et al. Tachycardia-induced failure alters contractile properties of canine ventricular myocytes. Cardiovasc Res. 1996; 32: 613–621.[CrossRef][Medline] [Order article via Infotrieve]
    
40. Spinale FG, Pearce AP, Schulte BA, et al. Ventricular function and Na⁺,K⁽⁺⁾-ATPase activity and distribution with chronic supraventricular tachycardia. Cardiovasc Res. 1991; 25: 138–144.[Abstract/Free Full Text]
    
41. Spinale FG, Clayton C, Tanaka R, et al. Myocardial Na⁺,K⁽⁺⁾-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1992; 24: 277–294.[Medline] [Order article via Infotrieve]
    
42. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003; 107: 2577–2582.[Abstract/Free Full Text]
    
43. Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991; 261: H308–H318.[Medline] [Order article via Infotrieve]
    
44. Spinale FG, Zellner JL, Tomita M, et al. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 1991; 69: 1058–1067.[Abstract/Free Full Text]
    
45. Gallagher JJ. Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited. J Am Coll Cardiol. 1985; 6: 1172–1173.[Medline] [Order article via Infotrieve]
    
46. Afonso MR, Franca HH. Sudden death and tachycardiomyopathy in a young man with incessant tachycardia [in Portuguese]. Arq Bras Cardiol. 1992; 58: 303–306.[Medline] [Order article via Infotrieve]
    
47. Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol. 1997; 30: 576–584.[Abstract]
    

This article has been cited by other articles:

				W. Rosamond, K. Flegal, K. Furie, A. Go, K. Greenlund, N. Haase, S. M. Hailpern, M. Ho, V. Howard, B. Kissela, et al. Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, January 29, 2008; 117(4): e25 - e146. [Full Text] [PDF]

				K. M Ho, D. J Sheridan, and T. Paterson Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Heart, November 1, 2007; 93(11): 1433 - 1440. [Abstract] [Full Text] [PDF]

				S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]

				W. Rosamond, K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M. Ho, V. Howard, B. Kissela, et al. Heart Disease and Stroke Statistics--2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, February 6, 2007; 115(5): e69 - e171. [Full Text] [PDF]

				T Date, T Yamane, K Inada, S Matsuo, S Miyanaga, K Sugimoto, K Shibayama, I Taniguchi, and S Mochizuki Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation Heart, November 1, 2006; 92(11): 1623 - 1627. [Abstract] [Full Text] [PDF]

				S. Arif and J.N. Townend Heart failure: be aware of reversible causes QJM, October 1, 2006; 99(10): 717 - 718. [Full Text] [PDF]

				Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF]

				Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF]

				T. Thom, N. Haase, W. Rosamond, V. J. Howard, J. Rumsfeld, T. Manolio, Z.-J. Zheng, K. Flegal, C. O'Donnell, S. Kittner, et al. Heart Disease and Stroke Statistics--2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, February 14, 2006; 113(6): e85 - e151. [Full Text] [PDF]

				Y. Tsuji, S. Zicha, X.-Y. Qi, I. Kodama, and S. Nattel Potassium Channel Subunit Remodeling in Rabbits Exposed to Long-Term Bradycardia or Tachycardia: Discrete Arrhythmogenic Consequences Related to Differential Delayed-Rectifier Changes Circulation, January 24, 2006; 113(3): 345 - 355. [Abstract] [Full Text] [PDF]

				H. Tatewaki, M. Masuda, T. Nishida, Y. Kaji, H. Ushinohama, S. Morita, and H. Yasui Successful Treatment of Tachycardia-Induced Cardiomyopathy With LVAD in a 12-Year-Old Boy Ann. Thorac. Surg., August 1, 2005; 80(2): e5 - e7. [Abstract] [Full Text] [PDF]

				G. W. Dec Recognition of the Apical Ballooning Syndrome in the United States Circulation, February 1, 2005; 111(4): 388 - 390. [Full Text] [PDF]

				Tachycardia-Induced Cardiomyopathy Journal Watch Cardiology, September 24, 2004; 2004(924): 4 - 4. [Full Text]

This Article Abstract Full Text (PDF) All Versions of this Article: 110/3/247    most recent 01.CIR.0000135472.28234.CCv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Ci